

DOWNSTAGING BREAST CANCER IN SUB-SAHARAN AFRICA: A REALISTIC TARGET?

ISABEL DOS-SANTOS-SILVA (TOP LEFT), DEPARTMENT OF NON-COMMUNICABLE DISEASE EPIDEMIOLOGY, LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, UK; **VALERIE MCCORMACK** (TOP RIGHT), SECTION OF ENVIRONMENT AND RADIATION, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE; **ELIMA JEDY-AGBA** (BOTTOM LEFT), INTERNATIONAL RESEARCH CENTER OF EXCELLENCE, INSTITUTE OF HUMAN VIROLOGY, ABUJA, NIGERIA; AND **CLEMENT ADEBAMOWO** (BOTTOM RIGHT), DEPARTMENT OF EPIDEMIOLOGY AND PUBLIC HEALTH, GREENEBAUM COMPREHENSIVE CANCER CENTER AND THE INSTITUTE OF HUMAN VIROLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, BALTIMORE, USA



Most breast cancer patients in high-income countries have a good prognosis. However, patients in sub-Saharan Africa (SSA) have poor prognosis largely because of advanced stage at presentation. Current evidence is consistent with the poor breast cancer survival in SSA being largely driven by long delays to diagnosis rather than a higher prevalence of aggressive disease subtypes, indicating that downstaging may be a viable and effective approach to reducing mortality from the disease in the region.

A diagnosis of breast cancer in most high-income countries has extremely good prognosis in the vast majority of women (1), but in many sub-Saharan African (SSA) countries its prognosis is extremely poor (2–4). In most settings at least 25% of women die within two years of diagnosis (3–5). The need to improve survival rates in affected SSA women is unquestionable, but strategies require sound epidemiologic evidence on fundamental features of this cancer, particularly in relation to the well-established heterogeneity of this tumour. Breast cancer comprises several subtypes – the potential to diagnose early will largely depend on the predominant subtypes present.

Herein, we highlight key features of the epidemiology of breast cancer in SSA. We then address the question of whether downstaging (Box), as an essential component of early curative

treatment, is a realistic target, by first examining the dominant subtypes in SSA, the challenges in determining them and whether they and/or other factors influence advanced disease stage at diagnosis. These “fundamentals” of breast cancer in SSA would shed light on the potential to improve survival, and lead to today’s pertinent question of how to achieve this within resource-limited settings. Throughout, we acknowledge the diversity of SSA populations, culturally, spatially and in access to healthcare.


Breast cancer burden in SSA

Like in many other parts of the world, breast cancer is the most common cancer in women in SSA (6). However, in contrast to high-income countries, where in 2012 there was on average one breast cancer death for every four women newly diagnosed with breast cancer, in SSA this ratio was one breast cancer death for every two new diagnoses, reflecting the poor survival from this disease in the region (Figure 1). In that year 48,000 SSA women died from breast cancer and 94,000 women were diagnosed with breast cancer (6). Future projections of incidence and mortality of breast cancer will depend greatly on SSA’s demographic transitions. After retractions at the height of the HIV/AIDS epidemic, today SSA’s population growth rates and life-expectancy are increasing at the fastest rates in the world (7). As a consequence, at 2012 age-specific mortality

Box: Downstaging symptomatic disease versus screening for asymptomatic disease

- ➔ Downstaging, also known as downwards stage migration, refers to the process of ensuring that symptomatic women, i.e. those with a palpable cancer or other clinically-detectable symptom, are diagnosed with earlier, and potentially curable, breast cancer rather than later, mainly incurable, disease.
- ➔ Screening aims to detect pre-clinical cancer lesions in asymptomatic women, i.e. women who have no clinically-detectable disease, through the use of mammography, often in combination with other imaging modalities (e.g. ultrasound).

Figure 1: Five-year breast cancer survival worldwide and in Africa as estimated by its proxy (1- mortality/incidence)



rates, a projected 81,000 breast cancer deaths, that is 11% of global breast cancer deaths will occur in SSA in 2030 (6). This death toll may be higher if there are, as are expected from fertility and lifestyle-related changes, increases in age-specific breast cancer incidence rates, but deaths could be avoided if survival rates are improved.

The SSA-wide picture has considerable between-setting differences. In 2012, estimated incidence rates were highest in South Africa, Mauritius and Nigeria and were at least two-times lower in countries such as Swaziland, The Gambia and Guinea (6). Estimates of incidence time trends are scarce, but the few available – e.g. from Uganda, Malawi and South Africa – show ~5% increases in rates per year (8-10). Poor health information systems have also hindered survival studies. Losses to follow-up of over 40% at three years are common, and this yields very unreliable 5-year survival estimates. For instance, 5-year survival estimates from Ethiopia have ranged from 27% to 46% (3). Nevertheless, five-year survival, as estimated by 1-mortality/incidence (11), also displays regional variations: estimates are higher in Southern Africa than in some Western African populations (Figure 1).

Is breast cancer in SSA a more aggressive disease?

It is often stated that breast cancer in SSA is a more aggressive disease than elsewhere. This perception stems from two main observations. Firstly, the average age at breast cancer diagnosis is ~10 years younger in SSA than in western countries (~50 years in SSA (6) vs. 63 years in the United States (6, 12)). This has been interpreted by some as an indication that the disease in SSA is a more aggressive fast-growing one

and of a different fundamental etiological origin. However, as breast cancer incidence rates in young, as in older, age-groups are actually lower in SSA than in high-income countries (6), the shift towards an earlier age at diagnosis is likely to simply reflect the much younger population of the region (~89.4% women in SSA were aged <50 years in 2017 vs. ~57.9% in more developed regions of the world (13)). In other words, a larger proportion of breast cancers occur at young pre-menopausal ages in SSA because women in these age-groups represent a larger proportion of the population in that region. Second, most breast cancers in SSA are diagnosed at advanced stages. This then leads to poorer outcomes as treatment options are more limited and less effective. Half of the studies included in a recent systematic review (14) reported that 70% or more of breast cancer patients were diagnosed at an advanced stage (TNM stages III and IV (15)), and although advanced stage may indicate the predominance of a more biologically aggressive form of disease, it may also be a consequence of long delays between onset of symptoms and diagnosis. These two possibilities are discussed below.

Breast cancer subtypes are usually identified in the clinical setting by immuno-histochemistry (IHC), which stains cancer cells according to the presence of estrogen (ER), progesterone (PR) and human epidermal growth factor-2 (HER2) receptors. ER-positive (ER+) cancers depend on oestrogen for their growth, so they can be treated with drugs to reduce either the effect of this hormone (e.g. tamoxifen) or its levels (e.g. aromatase inhibitors), and usually have a better prognosis (16). Women with HER2-positive (HER2+) cancers have a worse prognosis, but they respond to immunotherapy (i.e.

trastuzumab) in combination with chemotherapy (16). Cancers with no positive ER, PR or HER2 receptors, the so-called “triple negative” cancers, are some of the most aggressive forms of the disease for which there are no targeted treatments (16).

The relative proportions of breast cancer subtypes in SSA are central to the potential for, and strategies needed, to reduce breast cancer deaths in the region. Subtypes differ by environmental and lifestyle risk factors (17), in the contribution of inherited genetic mutations (18), in tumour growth rates pre-diagnosis – the speed of which determines the time window for down-staging – and, post-diagnosis, in disease aggressiveness and prognosis (19), and the choice and costs of targeted treatment modalities (16). If the predominant tumours are aggressive subtypes, the time window for downstaging (i.e. for early diagnosis of symptomatic disease; Box 1) would be short. On the other hand, if the predominant tumours are less aggressive subtypes, the window of opportunity for downstaging may be wider allowing for interventions to accelerate presentation and diagnosis, allowing earlier treatment that may cure the patient or significantly improve quality of life where cure is not possible.

ER+ subtypes account for ~80% of all breast cancers among White women (i.e. those of European ancestry) in the United States, but for a smaller proportion (~65%) among United States Black women (20). In SSA, some studies, albeit not all, have reported lower proportions of ER+ disease (21). These somewhat alarming results from small studies are often quoted, but, as outlined below, the overall picture differs. The reliability of ER testing is highly dependent on the quality of the procedures used for tissue sample collection, fixation, and receptor testing. Poor quality procedures (e.g. delays in processing tissue samples, inadequate fixation and dehydration procedures) lead to false ER-negative results. A recent systematic review (21) found marked between-study heterogeneity in the reported proportion of ER+ tumours in the region, with studies based on suboptimal procedures (e.g. archival tissue blocks) yielding lower ER+ frequency estimates whilst those based on better-quality (e.g. prospectively-collected) samples showing that two-thirds of breast cancers in SSA Black women were ER+, a frequency similar to that found among United States Black women. Further, in South Africa, from a nationwide study with receptor testing conducted under the same conditions and in the same laboratories, Black women had only a small excess of ER- disease; percentage of ER- disease was 34% compared to 25% in White women (22). Whilst this difference is important, and needs to be understood, the overlap of subtypes between the groups is notably large: 90% of Black patients have the same breast cancer subtype as their White counterparts.

The systematic review mentioned above (21) highlighted the

paucity of data on breast cancer subtypes in SSA, cautioning against any generalizations. High-quality procedures for tissue sample collection, processing and receptor testing, are needed for the histological diagnosis and receptor subtyping of breast cancer in SSA. These are already available in Southern Africa, but in Western and Eastern Africa only once this resource is widely available will it be possible to accurately determine the receptor-defined subtype distribution in SSA, and whether it varies across the region. Nevertheless, despite current uncertainties, the existing evidence points to the subtype distribution in many SSA settings not being greatly different from that seen in high-income countries, with most disease being ER+ and, hence likely to be less aggressive, with a long window for downstaging interventions, and potential curability.


Delays to diagnosis

Time to diagnosis of breast cancer comprises several components. A simplistic partition of this timeline starts at the (unobservable) time from clinical onset of symptoms, i.e. time when lesions become symptomatic and therefore clinically detectable, to their recognition by the woman; the time from symptom recognition to her first contact with a healthcare provider; and the time from first contact with a provider to a definitive diagnosis of breast cancer (23). There is strong evidence that a delay from symptom recognition to diagnosis of more than three months is associated with later stage at presentation and poorer survival (24). In high-income countries, the time interval from symptom recognition to a diagnosis is often less than 30 days (25–27). In contrast, in SSA, these delays are often greater than 6 months (28–35) (Figure 2). These long delays are consistent with breast cancers in SSA comprising predominantly slow-growing, less aggressive, ER+ subtypes. Most SSA studies reported average tumour sizes between 4 to 8 cm (14). Tumour growth models (36) predict that it would take ~12 and ~22 months for a tumour of 2 cm, the average size when a tumour becomes palpable, to grow to 4 cm and 6 cm respectively (Figure 3). These models are for other populations; nevertheless, their estimates provide a rough indication of the likely duration of the time window for downstaging the disease. Furthermore, reported delay times from SSA studies in Figure 2 are not widely different from model-expected times. This thus suggests a considerable time window representing a realistic opportunity to ensure women receive an earlier diagnosis of palpable disease.

Challenges to early breast cancer diagnosis and treatment

Several studies have shown that early stage breast cancer in SSA (3–5), as elsewhere (37), is associated with better survival


Figure 2: Reported delays in the presentation, diagnosis and treatment of breast cancer in sub-Saharan Africa (modified from Espina et al. (53)) and, for comparison, in more developed countries. (IQR: inter-quartile range; Md: median; Me: mean; wMe: weighted mean. A dashed line indicates that the estimate from the original publication shown here is likely to be an underestimation of the true average delay)



than late stage disease, consistent with early diagnosis and treatment leading to reductions in mortality from this disease.


Downstaging of symptomatic breast cancer, rather than screening of asymptomatic women, should be the priority in the region. Mammography screening is advocated for early breast cancer diagnosis in settings where breast cancer stage at diagnosis distributions reflect short intervals between a clinically-detectable symptom (e.g. a palpable lump) and breast cancer diagnosis, and where health systems can support wide-scale screening. Several reasons argue against this approach in SSA settings. Firstly, as the incidence of breast cancer in SSA is lower than in high-income countries, the yield of a screening programme will be low, that is, a large number of women would need to be screened to detect a true case of breast cancer thus shifting the balance between its benefits and harms towards the latter, and reducing its cost-effectiveness. Secondly, the aim of screening is to detect asymptomatic tumours before they give rise to symptoms or become palpable (Box 1); however, substantial delays to diagnosis in SSA occur after a tumour is palpable and, hence, clinically detectable (Figure 2). Thirdly, the implementation and running of a screening programme requires considerable levels of funding, administrative capability as well as infrastructure and technical resources; these are simply not available in low-resource settings such as those in SSA. Fourthly, screening can reduce breast cancer mortality only if women with suspicious

Figure 3: Average modelled breast tumour growth curves in western populations. The long delay times to diagnosis (Figure 2) and the large tumour sizes seen in SSA are not inconsistent with this model



screen-detected lesions, many of which will not be malignant breast cancer, have timely access to appropriate diagnosis and treatment. The addition of women with suspicious screen-detected lesions to those with symptomatic disease would place significant additional burden on already over-stretched healthcare systems in the region. It is worth noting that even in countries with a population-based mammographic screening programme, which has reached a high coverage, the majority of breast cancer patients present symptomatically (e.g. only 32% of all breast cancers in the United Kingdom in 2007 were

Figure 4: Breast cancer control in sub-Saharan Africa: policy recommendations and research priorities (BC: breast cancer; HIV: human immunodeficiency virus; IHC: immuno-histochemistry; SSA: sub-Saharan Africa)



screen-detected; 56% among those in the target age-group 50–69 years (38)). There is currently no conclusive evidence that screening asymptomatic women with low-technology approaches such as breast self-examination (BSE) or clinical breast examination (CBE) leads to reductions in breast cancer mortality (39), albeit CBE may be useful for downstaging symptomatic disease (as discussed below).

How can downstaging be achieved? The Breast Health Global Initiative and the Breast Cancer Initiative 2.5 recommend a stratified approach, with a phased implementation, for low-resource settings (40, 41). The first phase should focus on tackling health-system related barriers to early diagnosis of symptomatic breast cancer through, the provision of adequate training to healthcare professionals, development of standardized diagnostic and treatment guidelines and protocols as well as implementation of clear patient navigation pathways to ensure faster referral to tertiary care services. Initiatives to increase breast cancer awareness in the population should be promoted in addition to ensuring that the health system will be able to cope with the increasing demand in diagnostic capability that they will generate. Studies in rural Sudan (42) and Tanzania (43), as in India (44), have shown that breast cancer awareness campaigns coupled with CBE (performed by trained non-medical volunteers) are effective in downstaging the disease in these settings where the majority of women

present with advanced disease. Given that no conclusive evidence currently exists, a pertinent question is whether such downstaging will translate into mortality reductions. Some of these ongoing studies will be able to provide an answer to this question in the near future.

Early diagnosis must be coupled with early treatment if reductions in mortality are to be achieved. As no single subtype is rare in SSA, making IHC routinely available should be a priority unless robust local evidence suggests otherwise. In SSA settings where IHC testing is not available it may be reasonable to assume, on the basis of current evidence, that the majority of patients would benefit from anti-hormonal treatments particularly as they are low cost, easy to administer and have few side effects.

Research priorities for downstaging breast cancer

Research priorities for downstaging need to be established within a broader framework for breast cancer control in SSA (Figure 4). Appropriate recognition of breast cancer symptoms, improved access to health facilities and timely diagnosis of symptomatic patients are essential to downstage breast cancer in SSA. Understanding the influence of the factors that influence a woman's journey to breast cancer diagnosis and treatment is vital to the development of effective interventions. Studies in SSA (45–47) have found that delays to diagnosis are associated with a combination of woman-level (e.g. low educational level, poor socioeconomic status, living in a rural area, poor breast cancer awareness, belief in traditional or spiritual medicine) and health system-related factors (e.g. distance to nearest healthcare provider, number of healthcare providers visited prior to diagnosis, health professionals with poor breast cancer knowledge, unavailability of suitable diagnostic facilities, lack of appropriate referral pathways). However, the relative importance of these factors is likely to vary from setting to setting as a result of differences in sociocultural norms, economic development and healthcare systems. This is currently being investigated in the multi-country African Breast Cancer – Disparities in Outcomes (ABC-DO) study, a study on the determinants of breast cancer survival in five SSA countries (Namibia, Nigeria, South Africa, Uganda and Zambia) (48). Findings from this study, which will become available within the next two years, will provide a first indication of the extent to which woman-level and health system barriers to early diagnosis differ across settings in the region, as well as of their impact on stage at diagnosis and survival, and will provide the necessary evidence-base to design appropriate interventions for downstaging breast cancer. Such interventions will need to be properly evaluated not only in terms of their effectiveness in reducing stage at breast cancer diagnosis but, crucially, also on whether they

will ultimately translate into reductions in mortality from the disease.

For downstaging to reduce mortality from breast cancer it needs to be coupled with early treatment. Research on the factors that influence timely access to appropriate treatment regimens, and their uptake and adherence (49–52), is crucial. Accurate determination of the distribution of receptor-defined subtypes of breast cancer across the region should be regarded as a priority. Ideally, high-quality IHC should be available in clinical settings as part of the routine management of breast cancer patients to inform treatment choices but achieving this would not be trivial (e.g. need for well-equipped pathological laboratories, adequately trained technicians and pathologists). In the absence of this, large multi-country studies based on a common high-quality control protocol, which properly addresses the analytical issues which have plagued previous IHC studies, will help to assess the extent to which there is heterogeneity across the region (e.g. by sub-region, ethnicity) and would provide the necessary evidence-base to monitor trends in the subtype distribution as women adopt more westernized risk profiles (e.g. smaller family sizes, high BMI).

Finally, setting up and maintaining high-quality health information systems is essential for measuring the breast cancer burden in the population, monitoring future trends, and for proper evaluation of interventions that are rolled out into the community. Recent technological developments (e.g. in m-health) may help to achieve this in low-resource settings, particularly for patient follow-up which has been notoriously difficult to implement in SSA settings. ■

We are grateful to Mr Mathieu Laversanne and Ms Carolina Espina-Garcia, both from the International Agency for Research on Cancer (IARC), for having produced Figures 1 and 2 specifically for inclusion in this publication.

Isabel dos-Santos-Silva, MD, MSc, PhD is a Professor at the London School of Hygiene and Tropical Medicine. She was Senior Visiting Scientist at the International Agency for Research on Cancer in 2012–2016. She is currently a member of the Advisory Committee on Breast Cancer Screening, England. Breast cancer epidemiology is one of her main research interests, including investigations into genetic and non-genetic risk factors, biomarkers of susceptibility (e.g. breast density), prevention and control, and adverse health effects of the disease and its treatments. She coordinates studies in both high-income and low/middle-income countries including, jointly with V McCormack, the multi-country

African Breast Cancer – Disparities in Outcomes (ABC-DO) study.

Valerie McCormack, MSc, PhD is a scientist in the Section of Environment and Radiation, at the International Agency for Research on Cancer, France. She has a background in mathematics, medical statistics and epidemiology. Her current research focuses mainly on cancer epidemiology for prevention in sub-Saharan Africa. In breast cancer, her interests are in aetiology and outcomes in the African context; she has conducted investigations of breast cancer in South Africa, and co-leads the African Breast Cancer – Disparities in Outcomes (ABC-DO) study. She also coordinates multi-site oesophageal cancer aetiological studies across the African oesophageal cancer corridor and an international consortium on mammographic density.

Elima Jedy-Agba, MBBCh, MSc, PhD is a scientist at the Institute of Human Virology, Nigeria. She has a first degree in Medicine and Surgery from the University of Calabar, Cross River State Nigeria, and a Masters in Public Health and a PhD in Epidemiology from the London School of Hygiene and Tropical Medicine, UK. She is a World Cancer Research Fund International Fellow and a 50 for 50 Fellow of the International Agency for Research on Cancer, and a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Her research interests include cancer registration and cancer epidemiology with specific focus on breast cancer control in developing countries.

Clement Adebamowo, BMChB Hons, FWACS, FACS, ScD is Associate Director (Population Sciences), Greenebaum Comprehensive Cancer Center; Member of the Institute of Human Virology; Member of Institute of Global Health, University of Maryland School of Medicine. He is also Research Scientist at the Institute of Human Virology, Nigeria and Center for Bioethics and Research, Nigeria, and Coordinator of Nigerian National System of Cancer Registries. His research interests include cancer epidemiology, genomics, nutrition epidemiology and research ethics. He is PI of several NIH and Wellcome Trust funded research and training projects. He directs the cancer epidemiology graduate course in the Department of Epidemiology and Public Health, University of Maryland, Baltimore.

References

1. Allemani C, Weir HK, Carreira H et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015;385(9972):977-1010
2. Sankaranarayanan R, Swaminathan R. Cancer Survival in Africa, Asia, the Caribbean and Central America. Lyon, France: International Agency for Research on Cancer (IARC). *IARC Scientific Publication*, No 162; 2011
3. Kantelhardt E, Zerche P, Mathewos A et al. Breast cancer survival in Ethiopia: A cohort study of 1,070 women. *Int J Cancer*. 2014
4. Gakwaya A, Kigula-Mugambe JB, Kavuma A et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. *Br J Cancer*. 2008;99(1):63-7
5. Galukande M, Wabinga H, Mirembe F. Breast cancer survival experiences at a tertiary hospital in sub-Saharan Africa: a cohort study. *World J Surg Oncol*. 2015;13:220
6. Ferlay J, Soerjomataram I, Dikshit R et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2013. 2013. <http://globocan.iarc.fr> [accessed on 1/6/2017].
7. United Nations, Department of Economic and Social Affairs, Population Division. *World Population Prospects: The 2015 Revision, Key Findings and Advance Tables*. Working Paper No. ESA/P/WP.241. 2015
8. Wabinga HR, Namboose S, Amulen PM et al. Trends in the incidence of cancer in Kampala, Uganda 1991-2010. *Int J Cancer*. 2014;135(2):432-9
9. Misiri H, Dzumalala C, Adriss A et al. Cancer incidence in Malawi: Time trends in Blantyre 1996-2005 and predictions up to 2015. *Global Adv Res J Med and Med Sciences*. 2012;1(6):145-53.
Available from: <http://garj.org/garjms/7/2012/1/6/cancer-incidence-in-malawitime-trends-in-blantyre-1996-2005-and-predictions-up-to-2015#sthashjFnbJv8p.dpuf>.
10. Singh E, Joffe M, Cubasch H et al. Breast cancer trends differ by ethnicity: a report from the South African National Cancer Registry (1994-2009). *Eur J Public Health*. 2017;27(1):173-8
11. Asadzadeh VF, Karim-Kos HE, Janssen-Heijnen ML et al. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. *Eur J Public Health*. 2011;21(5):573-7
12. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Based on November 2015 SEER data submission, posted to the SEER web site. 2015. Available from: http://seer.cancer.gov/csr/1975_2013/ [accessed on 1/6/2017].
13. US Census Bureau. International Programs (<https://www.census.gov/population/international/data/idb/region.php?N=%20Results%20&T=10&A=aggregate&RT=1&Y=2017&R=55&C=->) [accessed on 1/6/2017].
14. Jedy-Agba E, McCormack V, Adebamowo C, dos-Santos-Silva I. Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. *Lancet Glob Health*. 2016;4(12):e923-e35
15. Edge SB, Compton CC, Fritz AG et al. (editors). *AJCC Cancer Staging Manual* (7th ed.). New York, NY: Springer; 2010
16. Senkus E, Kyriakides S, Ohno S et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26 Suppl 5:v8-30
17. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst*. 2011;103(3):250-63
18. Purrington KS, Slager S, Eccles D, Yannoukakis D et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. *Carcinogenesis*. 2014;35(5):1012-9
19. Blows FM, Driver KE, Schmidt MK et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med*. 2010;7(5):e1000279
20. National Cancer Institute Surveillance Epidemiology and End Results Program (SEER) <http://seer.cancer.gov/data/> [accessed 1/6/2017]
21. Eng A, McCormack V, dos-Santos-Silva I. Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. *PLoS Med*. 2014;11(9):e1001720
22. Dickens C, Duarte R, Zietsman A et al. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. *Cancer Epidemiol Biomarkers Prev*. 2014;23(11):2311-21
23. Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. *Front Public Health*. 2014;2:87
24. Richards MA, Smith P, Ramirez AJ et al. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. *Br J Cancer*. 1999;79(5-6):858-64
25. Arndt V, Sturmer T, Stegmaier C et al. Patient delay and stage of diagnosis among breast cancer patients in Germany -- a population based study. *Br J Cancer*. 2002;86(7):1034-40
26. Nosarti C, Crayford T, Roberts JV et al. Delay in presentation of symptomatic referrals to a breast clinic: patient and system factors. *Br J Cancer*. 2000;82(3):742-8
27. Arndt V, Sturmer T, Stegmaier C et al. Provider delay among patients with breast cancer in Germany: a population-based study. *J Clin Oncol*. 2003;21(8):1440-6
28. Ezeome ER. Delays in presentation and treatment of breast cancer in Enugu, Nigeria. *Niger J Clin Pract*. 2010;13(3):311-6
29. Ly M, Diop S, Sacko M et al. [Breast cancer: factors influencing the therapeutic itinerary of patients in a medical oncology unit in Bamako (Mali)]. *Bull Cancer*. 2002;89(3):323-6
30. Pace LE, Mpunga T, Hategekimana V et al. Delays in Breast Cancer Presentation and Diagnosis at Two Rural Cancer Referral Centers in Rwanda. *The Oncologist*. 2015;20(7):780-8
31. Ibrahim NA, Oludara MA. Socio-demographic factors and reasons associated with delay in breast cancer presentation: A study in Nigerian women. *The Breast*. 2012;21(3):416-8
32. Marcus TS, Lunda S, Fernandez L. Delayed breast cancer presentation: hospital data should inform proactive primary care. *Afr J Primary Health Care Family Planning* 2013;5: Art
33. Clegg-Lampety J, Dakubo J, Attobra YN. Why do breast cancer patients report late or abscond during treatment in ghana? A pilot study. *Ghana Med J*. 2009;43(3):127-31
34. Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW. Cancer care challenges in developing countries. *Cancer*. 2012;118(14):3627-35
35. Toure M, Nguessan E, Bambara AT, Kouassi YK, Dia JM, Adoubi I. [Factors linked to late diagnosis in breast cancer in sub-Saharan Africa: case of Cote d'Ivoire]. *Gynecol Obstet Fertil*. 2013;41(12):696-700
36. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ et al. Breast cancer tumor growth estimated through mammography screening data. *Breast Cancer Res*. 2008;10(3):R41
37. Walters S, Maringe C, Butler J et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. *Br J Cancer*. 2013;108(5):1195-208
38. Lawrence GK, Kearins O, Lagord C et al. The Second All Breast Cancer Report. Focusing on Inequalities: Variation in breast cancer outcomes with age and deprivation. UK: *National Cancer Intelligence Network (NCIN)*, 2011
39. Lauby-Secretan B, Scoccianti C, Loomis D et al. Breast-cancer screening--viewpoint of the IARC Working Group. *N Engl J Med*. 2015;372(24):2353-8
40. El Saghir NS, Adebamowo CA, Anderson BO et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. *Breast*. 2011;20 Suppl 2:S3-11
41. Anderson BO, Cazap E, El Saghir NS et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. *Lancet Oncol*. 2011;12(4):387-98
42. Abudris DO, Elsheikh A, Ali M et al. Breast-cancer screening with trained volunteers in a rural area of Sudan: a pilot study. *Lancet Oncol*. 2013;14(4):363-70
43. Ngoma T, Mandeli J, Holland JF. Downstaging cancer in rural Africa. *Int J Cancer*. 2015;136(12):2875-9
44. Sankaranarayanan R, Ramadas K, Thara S et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. *J Natl Cancer Inst*. 2011;103(19):1476-80
45. Jedy-Agba E, McCormack V, Olaomi O et al. Determinants of stage at diagnosis of breast cancer in Nigerian women: sociodemographic, breast cancer awareness, health care access and clinical factors. *Cancer Causes Control*. 2017;28(7):685-97.
46. Brinton L, Figueroa J, Adjei E et al. Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa. *Breast Cancer Res Treat*. 2017;162(1):105-14
47. Akuoko CP, Armah E, Sarpong T et al. Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa. *PLoS One*. 2017;12(2):e0171024.
48. McKenzie F, Zietsman A, Galukande M et al. African Breast Cancer--Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa. *BMJ Open*. 2016;6(8)
49. Adisa AO, Lawal OO, Adesunkanmi AR. Paradox of wellness and nonadherence among Nigerian women on breast cancer chemotherapy. *J Cancer Res Ther*. 2008;4(3):107-10
50. Anyanwu SN, Egwuonwu OA, Ihekwoaba EC. Acceptance and adherence to treatment among breast cancer patients in Eastern Nigeria. *Breast*. 2011;20 Suppl 2:S51-S3
51. Egwuonwu OA, Anyanwu SN, Nwofor AM. Default from neoadjuvant chemotherapy in premenopausal female breast cancer patients: what is to blame? *Niger J Clin Pract*. 2012;15(3):265-9
52. Oguntola AS, Adeoti ML, Akanbi OO. Non-adherence to the use of tamoxifen in the first year by the breast cancer patients in an African Population. *East Central Afr J Surgery*. 2011;16(1):52-6
53. Espina CM, McKenzie F, dos-Santos-Silva I. Delayed breast cancer presentation and diagnosis in African women: a systematic review. *Ann Epidemiol* 2017;27(10):659-671.